Brian A. Willis

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans

Patrick C. May, Brian A. Willis, Stephen L. Lowe et al. · Journal of Neuroscience · 2015 · 195 citations · Full text

Amyloid β, Neurodegenerative Diseases, Amyloid Lowering +15

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease

Alette M. Wessels, Pierre N. Tariot, Jennifer A. Zimmer et al. · JAMA Neurology · 2019 · 191 citations · Full text

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes

Sergey Shcherbinin, Cynthia Evans, Ming‐Chi Lu et al. · JAMA Neurology · 2022 · 175 citations · Full text

Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease

Paula T. Trzepacz, Peng Yu, Phani K. Bhamidipati et al. · Alzheimer s & Dementia · 2012 · 133 citations · Full text

Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease

Stephen L. Lowe, Brian A. Willis, Anne Hawdon et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2021 · 114 citations · Full text